3 Patent No. WO2013114185A1
4 Compared with their unencapsulated friendly bacteria strains. Del Piano M. et al. Evaluation of the intestinal colonization by microencapsulated probiotics supplement bacteria in comparison with the same uncoated strains. J Clin Gastroenterol. 2010 Sep; 44 Suppl 1:S42-6.
5 The Chinese University of Hong Kong
6 Zhang, Lin et al. “Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study.” Journal of gastroenterology and hepatology vol. 37,5 (2022): 823-831. doi:10.1111/jgh.15796
7 Customer survey conducted by G-NiiB GenieBiome Hong Kong in 2022 for customers who previously purchased our gut health products.
8 Wong, M. C. S. et al. (2023). Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study). Nutrients, 15(8), 1982.
9 Lau, R. I et al. (2023). A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. The Lancet. Infectious diseases, S1473-3099(23)00685-0.
10 Wong, M. C. S. et al. (2023). Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study). Nutrients, 15(8), 1982.
11 Lau, R. I et al. (2023). A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. The Lancet. Infectious diseases, S1473-3099(23)00685-0.
12 Wong, M. C. S. et al. (2023). Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study). Nutrients, 15(8), 1982.
13 Lau, R. I et al. (2023). A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. The Lancet. Infectious diseases, S1473-3099(23)00685-0.
15 Gillor O, Etzion A, Riley MA. The dual role of bacteriocins as anti- and probiotics. Appl Microbiol Biotechnol. 2008;81(4):591-606. doi:10.1007/s00253-008-1726-5
16 Fayol-Messaoudi D, Berger CN, Coconnier-Polter MH, Liévin-Le Moal V, Servin AL. pH-, Lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol. 2005;71(10):6008-6013. doi:10.1128/AEM.71.10.6008-6013.2005
17 Kamada N, Kim YG, Sham HP, et al. Regulated virulence controls the ability of a pathogen to compete with the gut microbiota. Science. 2012;336(6086):1325-1329. doi:10.1126/science.1222195
18 Tuomola EM, Ouwehand AC, Salminen SJ. The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. FEMS Immunol Med Microbiol. 1999;26(2):137-142. doi:10.1111/j.1574-695X.1999.tb01381.x
19 Campana R, van Hemert S, Baffone W. Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. Gut Pathog. 2017;9:12. Published 2017 Mar 6. doi:10.1186/s13099-017-0162-4
20 Zhang, L., Xu, Z., Mak, J. W. Y., Chow, K. M., Lui, G., Li, T. C. M., Wong, C. K., Chan, P. K. S., Ching, J. Y. L., Fujiwara, Y., Chan, F. K. L., & Ng, S. C. (2022). Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study. Journal of gastroenterology and hepatology, 37(5), 823–831. https://doi.org/10.1111/jgh.15796
21 Wang L, Cao H, Liu L, et al. Activation of epidermal growth factor receptor mediates mucin production stimulated by p40, a Lactobacillus rhamnosus GG-derived protein. J Biol Chem. 2014;289(29):20234-20244. doi:10.1074/jbc.M114.553800
22 Alvarez CS, Badia J, Bosch M, Giménez R, Baldomà L. Outer Membrane Vesicles and Soluble Factors Released by Probiotic Escherichia coli Nissle 1917 and Commensal ECOR63 Enhance Barrier Function by Regulating Expression of Tight Junction Proteins in Intestinal Epithelial Cells. Front Microbiol. 2016;7:1981. Published 2016 Dec 15. doi:10.3389/fmicb.2016.01981
23 Kumar M, Kissoon-Singh V, Coria AL, Moreau F, Chadee K. Probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2017;312(1):G34-G45. doi:10.1152/ajpgi.00298.2016